10X Genomics Hits New 52-Week High of $28.85, Reflecting Strong Growth

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 28.85 on May 29, 2026. This achievement marks a notable increase from its 52-week low of USD 8.95, reflecting a substantial upward trend over the past year. In terms of performance, 10X Genomics has recorded a 27.61% increase over the past year, closely trailing the S&P 500's performance of 28.21%. The company's market capitalization stands at USD 2,132 million, indicating its position within the small-cap segment of the market. Despite being loss-making, 10X Genomics continues to navigate the competitive landscape of the biotechnology industry. The company currently has a negative return on equity of -10.80% and a debt-to-equity ratio of -0.64, which suggests a unique financial structure. Additionally, the stock does not offer a dividend yield, aligning with many growth-focused biotech firms that reinvest earnings into research and development.